Evidence map›Paper›PMID 39938943›Full record

Trial reportHeart (British Cardiac Society)2025

Age-stratified effects of intravenous ferric derisomaltose in heart failure with iron deficiency: insights from the IRONMAN trial.

Shirley Sze, Iain Squire, Paul R Kalra, John G Cleland, Mark C Petrie, Philip A Kalra, Fozia Ahmed, Prithwish Banerjee, Christopher J Boos, Callum Chapman and 13 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Heart (British Cardiac Society), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02642562 (Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02642562 phase4completednot on this map

Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN)

TypeinterventionalSponsorUniversity of GlasgowRan2016 to 2022Enrolled1,160ConditionsChronic Heart Failure, Iron Deficiency, Left Ventricular Systolic DysfunctionArmsFerric Derisomaltose
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Shirley SzeDepartment of Cardiovascular Sciences, University of Leicester, Leicester, UK.ORCID 0000-0002-0226-5083
Iain SquireDepartment of Cardiovascular Sciences, University of Leicester, Leicester, UK.ORCID 0000-0002-6282-4318
Paul R KalraDepartment of Cardiology, Portsmouth Hospitals University NHS Trust, Portsmouth, UK.ORCID 0000-0002-5288-3074
John G ClelandSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.ORCID 0000-0002-1471-7016
Mark C PetrieSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Philip A KalraDepartment of Renal Medicine, Salford Royal Hospitals NHS Trust, Salford, UK.
Fozia AhmedManchester Heart Centre, Manchester University NHS Foundation Trust, Manchester, UK.
Prithwish BanerjeeDepartment of Cardiology, University Hospitals Coventry & Warwickshire, Coventry, UK.
Christopher J BoosDepartment of Cardiology, University Hospitals Dorset, Dorset, UK.
Callum ChapmanChelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Peter James CowburnDepartment of Cardiology, University Hospital Southampton, Southampton, UK.ORCID 0000-0001-6210-2203
Lana DixonRoyal Victoria Hospital, Belfast, UK.
Simon DuckettDepartment of Cardiology, University Hospital North Midlands, Stoke-on-Trent, UK.
Rebecca LaneRoyal Brompton and Harefield Hospital, London, UK.
Paul FoleyGreat Western Hospitals NHS Foundation Trust, Swindon, UK.
Ninian N LangSchool of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
Kristopher LyonsAntrim Area Hospital, Antrim, UK.
Robin RaySt George's University Hospitals NHS Foundation Trust, London, UK.
Rebekah SchiffGuy's and St Thomas' Hospitals NHS Trust, London, UK.
Elizabeth A ThomsonRobertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Michele RobertsonRobertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
Ian FordRobertson Centre for Biostatistics, University of Glasgow, Glasgow, UK ian.ford@glasgow.ac.uk.
IRONMAN Study group

Funding

British Heart Foundation CS/15/1/31175
6 · The paper itself

Abstract

backgroundIntravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency. However, its effects across different age groups remain unclear. This analysis of the Effectiveness of Intravenous Iron Treatment versus Standard Care in Patients with Heart Failure and Iron Deficiency (IRONMAN) trial explored the efficacy and safety of FDI across age groups.

methodsThe IRONMAN trial was a prospective, open-label, blinded end point randomised controlled trial enrolling patients with HFrEF and iron deficiency. This prespecified analysis stratified the population into four quarters by age group: <67 years, 67-73 years, 74-79 years, >79 years. The primary outcome was a composite of recurrent heart failure hospitalisations and cardiovascular death. Secondary outcomes included changes in haemoglobin and quality of life. Clinical outcomes comparing FDI versus usual care in each age subgroup were analysed by the method of Lin

resultsAmong 1137 randomised patients (median age 73 years), the primary outcome rate ratio (FDI vs usual care) was 0.87 (95% CI 0.61 to 1.23) in patients <67 years, 0.93 (95% CI 0.66 to 1.32) in those aged 67-73 years, 0.88 (95% CI 0.59 to 1.33) in those aged 74-79 years and 0.66 (95% CI 0.45 to 0.96) in those aged >79 years (p-interaction=0.38). Improvements in haemoglobin and quality of life scores at 4 months did not differ statistically across age groups (p-interaction=0.92 and 0.64, respectively). Older patients were more symptomatic at baseline, with higher N-terminal-pro B-type natriuretic peptide levels and poorer renal function, but safety outcomes did not differ across age groups.

conclusionsWe found no evidence that the effects of FDI on heart failure hospitalisations, cardiovascular death, haemoglobin and quality of life differed by age. These findings support its use in patients with HFrEF and iron deficiency, including older adults. TRIAL REGISTRATION NUMBER: NCT02642562.

Indexed as

Anemia, Iron-DeficiencyDisaccharidesFerric CompoundsHeart FailureMaltoseAdministration, IntravenousAgedAged, 80 and overAge FactorsFemaleHemoglobinsHospitalizationHumansMaleMiddle AgedProspective StudiesDisaccharidesFerric CompoundsHemoglobinsMaltoseheart failure

Identifiers

PMID39938943
PMCPMC12229076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.